Key takeaways
Timing is key. Earlier cancer screening can improve outcomes and shift spending away from more intensive late-stage treatment.
Gaps remain. Recent analyses of patients diagnosed with cancer show progress—but there are persistent gaps in numerous screenings.
Precision outreach is the next opportunity. Identify who remains unscreened, understand why, and remove the barrier.
Health plans and employers are under pressure to manage rising healthcare costs while improving quality, member experience, and health equity. Preventive cancer screening is one of the few strategies that can advance all four priorities at once.
Screening is more than a compliance measure or a quality score. It can find cancer before symptoms appear, when disease is often more treatable and care may be less intensive. Modeling published in JAMA Network estimated that a 10-percentage-point increase in recommended breast, colorectal, and cervical cancer screening could prevent thousands of deaths among eligible U.S. residents over their lifetimes.
The operational question is no longer whether screening works. It is how organizations can help more eligible people complete the right screening at the right time.
Cancer is often silent. A person may feel healthy while early-stage disease develops. Once symptoms emerge, treatment can become more invasive, complex, and expensive.
Behind a late-stage diagnosis may be a missed mammogram, delayed colonoscopy, skipped low-dose CT scan, or lapse in recommended follow-up. Each is a care gap and an opportunity to intervene earlier.
Data can help health plans and employers distinguish broad population needs from specific access problems. That distinction matters because the people who remain unscreened may face multiple, overlapping barriers and may not respond to a general reminder campaign.
Among patients diagnosed with breast cancer, the share with evidence of screening before diagnosis rose from 90% in 2019 to 97% in 2025. The proportion with no prior screening fell from 10% to 3%.
Yet the remaining gap deserves attention. Among unscreened patients, the metastatic rate increased from 10% in 2019 to 22% in 2025, after reaching 27% in 2024. Better overall performance can therefore coexist with greater risk in the small group still being missed. The implication is clear: complement broad mammography promotion with precise outreach to people facing persistent access, engagement, geographic, or socioeconomic barriers.
Colorectal screening can identify and remove precancerous polyps, making it both an early-detection strategy and a prevention tool. Among patients later diagnosed with colorectal cancer, prior screening increased from 38% in 2019 to 60% in 2025. Even so, 40% of those diagnosed in 2025 had no evidence of prior screening.
Organizations can help by offering convenient options, communicating clearly about eligibility, and supporting scheduling and follow-up. Stool-based testing may reduce friction for some people, while others may need help navigating colonoscopy preparation, transportation, or referrals.
Lung cancer screening targets a defined high-risk population, but eligible people may be difficult to identify when smoking history is incomplete. The share of patients with lung cancer who had been screened before diagnosis rose from 44% in 2019 to 60% in 2025. Screening within the prior year increased from 42% to 52%. Still, 40% of patients diagnosed in 2025 had no documented prior screening.
Combining claims, pharmacy, eligibility, and available clinical data can help identify candidates for outreach. Clear education and connections to low-dose CT resources can then move care from reaction toward earlier detection.
Prostate cancer screening decisions should be made with a healthcare provider based on individual factors and the benefits and potential risks of screening. Among patients diagnosed with prostate cancer, prior screening rose from 39% in 2019 to 67% in 2025, while screening within the previous 365 days increased from 34% to 45%.
The 22-point gap between ever screened and recently screened suggests a continuity challenge. One-third of patients diagnosed in 2025 had no evidence of prior screening. Better reminders, follow-up workflows, and shared decision-making can help keep appropriate screening from becoming a one-time event.
Screening gaps are not evenly distributed. Limited awareness, transportation challenges, cost concerns, fear, access constraints, and weak referral systems can all reduce participation. A single campaign cannot solve every barrier.
A more effective strategy starts with three questions:
Who is missing recommended screening? Use trusted, integrated data to identify gaps by cancer type, risk, geography, and population segment.
What is preventing action? Look beyond the rate itself to understand where eligibility identification, access, scheduling, communication, or follow-up breaks down.
Which intervention fits the barrier? Tailor reminders, navigation, benefits education, convenient testing options, provider prompts, and community partnerships to the people most likely to benefit.
Measurement should continue after outreach. Track screening completion, recent versus historical screening, follow-up after abnormal results, stage at diagnosis, cost, and disparities across populations. Transparent methods and consistent definitions help stakeholders trust the results and improve programs over time.
Preventive cancer screening connects quality, affordability, experience, and equity. The data shows meaningful progress, but it also reveals where broad improvement can mask concentrated risk.
For health plans and employers, the next step is to turn insight into precise action: find the people still being missed, design the barriers they face, and measure whether interventions lead to timely screening and earlier diagnosis. Truven understands that each completed screening is more than a metric. It is a chance to change the course of care before cancer becomes a crisis.
See how we can help.